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Leptomeningeal carcinomatosis (LMC) is a rare, but rapidly fatal clinical condition. It occurs in approximately 5% to 18% of lung carcinoma cases,1–3 and tumor-specific 
occurrence of LMC from lung cancer ranges from 10% to 29%.4,5 The time from the date 
of diagnosis of lung cancer to the date of diagnosis of LMC was 2 days to 8 years (median 
407 days).6 In general, LMC occurs in patients with widely disseminated and progressive 
systemic solid cancer.2 Novel effective anticancer treatments have improved the survival of 
patients with advanced non–small-cell lung cancer (NSCLC), which leads to an increasing 
incidence of LMC.7 Adenocarcinomas are the most common solid tumors to metastasize to 
the meninges.2 Especially in lung cancer, more than 75% of the incidence of LMC is found 
to be related to an adenocarcinoma histopathology.1,2,7,8
With the expansion of therapeutic options for systemic treatment of NSCLC, including 
targeted therapies, the landscape for treating LMC is changing. Data on whether the hydro-
philic antifolate pemetrexed is able to pass the blood–brain barrier are limited,9 although 
it has demonstrated activity within the central nervous system.10 Epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs) are able to cross the blood–brain barrier 
and have shown efficacy in the treatment of brain metastases and LMC.11–13 Most of the data 
about the treatment of LMC and its efficacy were collected decades before the approval of 
pemetrexed, bevacizumab, EGFR TKIs, and anaplastic lymphoma kinase (ALK) inhibitors. 
Even if intraventricular chemotherapy (IVC) is a preferred treatment for LMC, there are no 
universally accepted data supporting its effectiveness.
Gwak and colleagues,14 whose report is accompanied by this editorial, investigated 
IVC in a cohort of 105 NSCLC patients. This is the largest report of NSCLC patients with 
LMC, who were rather homogenously treated. Every IVC, which consisted of methotrexate 
as single-agent or in a triple combination with cytarabine and hydrocortisone, was adminis-
tered by means of an intraventricular reservoir (Ommaya [Baxter; Heyer-Schulte, Deerfield, 
IL] or Chemoport [Celsite; B. Braun, Boulogne Cedex, France]). Although the authors per-
formed a retrospective study, it is to their credit that some promising data about the efficacy 
of IVC for NSCLC patients are now available.
The investigators did not only calculate survival times, but also applied additional 
means to determine the response to IVC: they repeated measurements of the intracranial 
pressure (ICP), they used predetermined criteria for response assessment in cerebrospinal 
fluid (CSF), and they tentatively evaluated LMC-related symptoms.
The authors report that IVC can palliate LMC-associated symptoms. Thirty-
four of 81 patients (42%) with headache and nausea or vomiting at the time LMC was 
diagnosed, showed an improvement after IVC. Among 54 patients with increased ICP 
at the entry of the treatment, 20 patients (37%) achieved normal ICP after the IVC. 
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A complete CSF cytology conversion was achieved in 
eight patients (8%), and an additional 18 patients (17%) 
showed a partial remission of CSF cytology at the end of 
the IVC.
Furthermore, it was shown that IVC can prolong 
patients’ survival. A time-dependent covariate analysis model 
revealed a significant increase of survival in proportion to the 
number of IVC courses (hazard ratio = 0.95, 95% confidence 
interval: 0.91–99, p = 0.005), which implies that IVC resulted 
in improved patients’ survival. However, patients received 
not only IVC (n = 22), but also IVC plus systemic therapy 
(n = 53), and IVC plus radiotherapy (n = 30). The group that 
experienced the most profound benefit with a survival of 15.8 
months (n = 7) received systemic chemotherapy and EGFR 
TKI in addition to IVC. Although the numbers are small, this 
highlights the differential effects that can be achieved in the 
era of targeted therapy when patients are selected.
Lee and colleagues7 reported in the February 2013 issue 
of the Journal of Thoracic Oncology that IVC, whole-brain 
radiotherapy, and EGFR-TKI use might improve clinical out-
comes, mainly in NSCLC patients with LMC, good perfor-
mance status, low initial CSF protein concentration, and white 
blood cell counts. However, treatment for LMC consisted of 
IVC alone in 44 patients, IVC plus systemic therapy in 18 
patients, IVC plus whole-brain radiotherapy in 29 patients, all 
three treatments in 18 patients, and other treatments without 
IVC in 20 patients. Patients who received IVC survived longer 
than patients who did not receive IVC (17 versus 8 weeks). 
Unfortunately, no data on improvement of LMC-associated 
symptoms, CSF or ICP response were reported.
The abovementioned study from Lee and colleagues,7 
and the study published by Gwak and colleagues in this issue, 
included only Asian patients treated in Goyang or Seoul, 
Republic of Korea. Although their results cannot be assigned 
to other patient populations, there is some clear evidence that 
NSCLC patients with LMC benefit from IVC treatment.
Both the retrospective studies mentioned that the 
diversity of the additional treatment modalities (e.g., sys-
temic treatment or radiotherapy) limits the conclusions, 
which could be drawn from their results. Future prospective 
studies will have to verify the reported results. As personal-
ized therapy of NSCLC becomes more and more common, 
the establishment of factors predicting benefit from IVC is 
an unmet need, and Gwak and colleagues describe some 
potential predictive factors. Considering the fatal clinical 
courses of NSCLC patients with LMC, a more active treat-
ment strategy emphasizing the use of IVC may be associated 
with improvement of clinical outcomes of NSCLC patients 
suffering from LMC.
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